Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment
Year: 2026
Type: article
Abstract: Background Direct detection of circulating chimeric antigen receptor T (CAR-T) cells by flow cytometry provides information complementary to B-cell aplasia during immune monitoring after anti-CD19 CAR-T therapy. We describe the implementation and operational assessment of a multiparametric flow cytometry workflow for anti-CD19 CAR-T cell monitoring within an academic point-of-care cellular therapy program in Uruguay. Methods The assay was established for CAR-T product control and post-infusion monitoring. Technical implementation used an 8-color production panel and a locally adapted clinical monitoring panel on a 13-color DxFLEX cytometer. CAR detection used a biotinylated CD19 CAR Detection Reagent followed by PE-conjugated anti-biotin. Reagent titration, gating strategy, and an analytical sensitivity framework based on previously published criteria were assessed. B-cell aplasia was evaluated in a separate 10-color tube. Results The workflow was integrated into routine laboratory practice and applied during the initial clinical phase of the program. A working condition of 2 µL of CD19 CAR Detection Reagent and 2 µL of PE-conjugated anti-biotin were selected according to signal-to-noise performance and reagent use. For low-frequency interpretation, the analytical framework used a limit of blank of 8 events, a limit of detection of 13 events, and a lower limit of quantification of 22 events, adopted from published criteria rather than derived from a complete local recalculation. The method enabled direct CAR-T detection, assessment of B-cell aplasia, and characterization of CD4/CD8 distribution within the CAR-positive population. Conclusion Flow cytometry provided an integrated, locally available immune-monitoring strategy for an academic anti-CD19 CAR-T program, combining direct CAR-T detection with assessment of the B-cell compartment and T-cell phenotype. This operational experience may inform cellular therapy programs working under similar resource and implementation conditions.
Source: Frontiers in Hematology
Authors: Marcela Barrios(Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing), Maria Inés Pereira, Vittoria Ceriani(Formal analysis, Writing – review & editing), Lucía D’Andrea(Visualization, Writing – review & editing), Luis Castillo(Conceptualization, Investigation, Resources, Supervision, Validation, Writing – review & editing)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,353
OpenAlex ID: W7234201823
